1.Schlesser MA, Altshuler KZ. The genetics of affective disorder: data, theory, and clinical applications. Hosp Community Psychiatry. 1983; 34(5): 415–422.
2.Angst J. A clinical analysis of the effects of tofranil in depression: longitudinal and follow-up studies: treatment of blood-relations. Psychopharmacologia. 1961; 2: 381–407.
3.Pare CM, Mack JW. Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J Med Genet. 1971; 8(3): 306–309.
4.Wadelius M, Chen LY, Downes K, etal. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005; 5(4): 262–270.
5.Duman RS, Newton SS. Epigenetic marking and neuronal plasticity. Biol Psychiatry. 2007; 62(1): 1–3.
6.Kang HJ, Kawasawa YI, Cheng F, etal. Spatio-temporal transcriptome of the human brain. Nature. 2011; 478(7370): 483–489.
7.Laje G, Cannon DM, Allen AS, etal. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol. 2010; 13(6): 715–724.
8.Hu XZ, Rush AJ, Charney D, etal. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007; 64(7): 783–792.
9.Lesser IM, Castro DB, Gaynes BN, etal. Ethnicity/race and outcome in the treatment of depression: results from STAR*D. Med Care. 2007; 45(11): 1043–1051.
10.Laje G, Perlis RH, Rush AJ, McMahon FJ. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv. 2009; 60(11): 1446–1457.
11.Khan A, Detke M, Khan SR, Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis. 2003; 191(4): 211–218.
12.Fournier JC, DeRubeis RJ, Hollon SD, etal. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010 ; 303(1): 47–53.
13.Trivedi MH, Rush AJ, Wisniewski SR, etal. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1): 28–40.
14.Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 2008; 8(2): 90–100.
15.McMahon FJ, Buervenich S, Charney D, etal. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006; 78(5): 804–814.
16.Peters EJ, Slager SL, Kraft JB, etal. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008; 3(4): e1872.
17.Mrazek DA, Rush AJ, Biernacka JM, etal. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B(3): 341–351.
18.GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013; 170(2): 207–217.
19.Rasmussen HB, Werge TM. Novel procedure for genotyping of the human serotonin transporter gene-linked polymorphic region (5-HTTLPR)—a region with a high level of allele diversity. Psychiatr Genet. 2007; 17(5): 287–291.
20.Serretti A, Kato M, De RD, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007; 12(3): 247–257.
21.Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010; 68(6): 536–543.
22.Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004; 61(11): 1163–1169.
23.Hu XZ, Rush AJ, Charney D, etal. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007 July64(7): 783–792.
24.Kraft JB, Peters EJ, Slager SL, etal. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry. 2007; 61(6): 734–742.
25.Paddock S, Laje G, Charney D, etal. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007; 164(8): 1181–1188.
26.Horstmann S, Lucae S, Menke A, etal. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology. 2010; 35(3): 727–740.
27.Green E, Craddock N. Brain-derived neurotrophic factor as a potential risk locus for bipolar disorder: evidence, limitations, and implications. Curr Psychiatry Rep. 2003; 5(6): 469–476.
28.Saarelainen T, Hendolin P, Lucas G, etal. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci. 2003; 23(1): 349–357.
29.Egan MF, Kojima M, Callicott JH, etal. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003; 112(2): 257–269.
30.Ventriglia M, Bocchio Chiavetto L, Benussi L, etal. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol Psychiatry. 2002; 7(2): 136–137.
31.Hwang JP, Tsai SJ, Hong CJ, etal. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiology Aging. 2006; 27(12): 1834–1837.
32.Ribeiro L, Busnello JV, Cantor RM, etal. The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport. 2007; 18(12): 1291–1293.
33.Schumacher J, Jamra RA, Becker T, etal. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry. 2005; 58(4): 307–314.
34.Hong CJ, Huo SJ, Yen FC, etal. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology. 2003; 48(4): 186–189.
35.Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet. 2003; 123(1): 19–22.
36.Chen L, Lawlor DA, Lewis SJ, etal. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(6): 814–821.
37.Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006; 1118(1): 176–182.
38.Anttila S, Huuhka K, Huuhka M, etal. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. J Neural Transm. 2007; 114(8): 1065–1068.
39.Domschke K, Lawford B, Laje G, etal. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2010; 13(1): 93–101.
40.Zarate CA Jr., Singh JB, Carlson PJ, etal. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856–864.
41.Liu RJ, Lee FS, Li XY, etal. Brain-derived neurotrophic factor Val66Metallele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012; 71(11): 996–1005.
42.Laje G, Lally N, Mathews D, etal. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012; 72(11): e27–e28.
43.Garriock HA, Kraft JB, Shyn SI, etal. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010; 67(2): 133–138.
44.Ising M, Lucae S, Binder EB, etal. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009; 66(9): 966–975.
45.Uher R, Perroud N, Ng MY, etal. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010; 167(5): 555–564.
46.Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(7): 1553–1557.
47.Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007; 9(12): 819–825.
48.Huezo-Diaz P, Perroud N, Spencer EP, etal. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol. 2012; 26(3): 398–407.
50.Perlis RH, Purcell S, Fava M, etal. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007; 64(6): 689–697.
51.Laje G, Paddock S, Manji H, etal. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007; 164(10): 1530–1538.
52.Menke A, Lucae S, Kloiber S, etal. Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry. 2008; 165(7): 917–918.
53.Laje G, Allen AS, Akula N, etal. Genome-wide Association Study of Suicidal Ideation Emerging During Citalopram Treatment of Depressed Outpatients. Pharmacogenet Genomics. 2009; 19(9): 666–674.
54.Menke A, Domschke K, Czamara D, etal. Genome-wide association study of antidepressant treatment-emergent suicidal ideation. Neuropsychopharmacology. 2012; 37(3): 797–807.
55.Perroud N, Uher R, Ng MY, etal. Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J. 2012; 12(1): 68–77.
56.Perroud N, Aitchison KJ, Uher R, etal. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology. 2009; 34(12): 2517–2528.
57.Grof P, Duffy A, Cavazzoni P, etal. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002; 63(10): 942–947.
58.McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010; 11(10): 1439–1465.
59.Brandish PE, Su M, Holder DJ, etal. Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron. 2005; 45(6): 861–872.
60.Popkie AP, Zeidner LC, Albrecht AM, etal. Phosphatidylinositol 3-kinase (PI3 K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem. 2010; 285(53): 41337–41347.
61.Yu Z, Ono C, Sora I, Tomita H. Effect of chronic lithium treatment on gene expression profile in mouse microglia and brain dendritic cells. Nihon Shinkei Seishin Yakurigaku Zasshi. 2011; 31(2): 101–102.
62.Perlis RH, Dennehy EB, Miklowitz DJ, etal. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord. 2009; 11(4): 391–400.
63.Squassina A, Manchia M, Borg J, etal. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011; 12(11): 1559–1569.
64.Schulze TG, Alda M, Adli M, etal. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology. 2010; 62(1): 72–78.
65.Chung WH, Hung SI, Hong HS, etal. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428(6982): 486.
66.McCormack M, Alfirevic A, Bourgeois S, etal. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; 364(12): 1134–1143.